Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD)

Similar documents
Respiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician

PFT Interpretation and Reference Values

HOSPITAL RECORD ABSTRACTION FORM

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

Guideline for the Diagnosis and Management of COPD

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene

What do pulmonary function tests tell you?

Pulmonary Pearls. Medical Pearls. Case 1: Case 1 (cont.): Case 1: What is the Most Likely Diagnosis? Case 1 (cont.):

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

RESPIRATORY EMERGENCIES. Michael Waters MD April 2004

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation

Current Approaches to Asthma & COPD

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

Basic mechanisms disturbing lung function and gas exchange

Referring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL

Pharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08

Pulmonary Pathophysiology

GOALS AND INSTRUCTIONAL OBJECTIVES

Coexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis

Provider Respiratory Inservice

Decramer 2014 a &b [21]

Pulmonary Function Testing. Ramez Sunna MD, FCCP

Chronic Obstructive Pulmonary Disease Guidelines and updates

COPD: A Renewed Focus. Disclosures

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute

3 COPD Recognition and Diagnosis: Approach to the Patient with Respiratory Symptoms

COPD. Helen Suen & Lexi Smith

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

MEDICAL ASSISTANCE BULLETIN

Exacerbations of COPD. Dr J Cullen

SPIROMETRY. Marijke Currie (CRFS) Care Medical Ltd Phone: Copyright CARE Medical ltd

Differential diagnosis

Lecture Notes. Chapter 3: Asthma

Chapter 10 Respiratory System J00-J99. Presented by: Jesicca Andrews

REQUISITION FOR DIAGNOSTIC SERVICES

The role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE

Triennial Pulmonary Workshop 2012

Pulmonary Function Testing The Basics of Interpretation

Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects

RESPIRATORY CARE IN GENERAL PRACTICE

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs

EXACERBATION ASSESSMENT FORM

COPD Diagnosis, Management and Program

Question by Question (QXQ) Instructions for the HCHS/SOL Heart Failure Diagnosis Form (HFD)

How to distinguish between uncontrolled and severe asthma

EXACERBATION ASSESSMENT FORM

COPD exacerbation. Chiara Maruggi, PGY2

Basic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic

Known Allergies: Shellfish. Symptoms: abdominal pain, nausea, diarrhea, or vomiting. congestion, trouble breathing, or wheezing.

Chronic Obstructive Pulmonary Disease

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

COPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust

OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

Session Guidelines. This is a 15 minute webinar session for CNC physicians and staff

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Asthma COPD Overlap (ACO)

Over the last several years various national and

Fariba Rezaeetalab Associate Professor,Pulmonologist

REFERRAL GUIDELINES RESPIRATORY

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX

COPD: Current Medical Therapy

Lecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)

COPD. Stan Kellar, MD. Physiology 11/4/2014. Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine

COPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer

Allwin Mercer Dr Andrew Zurek

Core Content In Urgent Care Medicine Release Date: December 1, 2009 Review Date: January 31, 2011 Expiration Date: November 30, 2014

Spirometry: Introduction

The objectives of the pre-anaesthetic assessment

62 year old man with a cough! Dr. Aflah Sadikeen Consultant Respiratory Physician Colombo

Supplementary Online Content

Drug prescriptions (Pharm) Exposure (36/48 months)

Pulmonary Function Testing

Peak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation

Chronic obstructive lung disease. Dr/Rehab F.Gwada

Sample Case Study. The patient was a 77-year-old female who arrived to the emergency room on

2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information

This is a cross-sectional analysis of the National Health and Nutrition Examination

Update on Pulmonary Diseases. Jeffrey Lessar, MD

Supplementary appendix

Chronic obstructive pulmonary disease

Author(s): Frank Madore (Hennepin County Medical Center), MD 2012

Respiratory diseases in Ostrołęka County

Common Pulmonary Problems. Diana Coffa, MD Residency Program Director UCSF Department of Family and Community Medicine

Respiratory Medicine

Objectives. Pulmonary Assessment 12/13/2017

A Place For Airway Clearance Therapy In Today s Healthcare Environment

What is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing

Pulmonary Function Tests. Mohammad Babai M.D Occupational Medicine Specialist

QUESTION-BY-QUESTION INSTRUCTIONS FOR MMCC HEART FAILURE FINAL DIAGNOSIS FORM (HDX)

Transcription:

Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD) A Pulmonary Diagnosis Form is filled out by the reviewer for all medical records that are sent to them for review by the CSCC. Initially, events will be classified by 2 independent reviewers and disagreements will be classified by an adjudicator. Along with each medical record will be an Event Summary Form (ESF). The ESF is a 1 page summary of information abstracted from the medical records. It also contains selected information from the participants study visit. The first section of the form is called administrative information (0A-0D). When in electronic form, parts of this will be filled out by the CSCC. For training, please fill this out. A0. Enter date that you (the reviewer) completed the form. B0. Enter your staff or reviewer ID number. It is 3 digits. C0. Event ID. This number is assigned by the CSCC. It will start with a letter representing the HCHS/SOL field center site. It is stamped on the top of the medical record. D0. Event Date. Enter the date of arrival or the earliest date on the medical record.

CLRD Decision Flowchart CLRD Sub types (not mutually exclusive) CLRD exacerbation STOP No/unknown: no prior meds AND no PMH AND no new Dx COPD: NOT: PFT PROB: PMH COPD HIGH PR: qualitative PFT DEF: +PFT None: no Sx or Signs Emphysema: Probable: old meds OR PMH or new Dx NOT=negative CT PROB=PMH emphysema DEF=+CXR or +CT Probable: probable CLRD plus Sx Highly probable: plus subjective evidence (eg, PFT confirmed COPD ) Chronic bronchitis: PROB: PMH chronic bronchitis HIGH PR: prior bronchitis event within 24 months DEF: 3mo x 2 years (MRC) Highly probable: plus steroids LONE vs COMORBID Asthma: Definite: plus objective evidence (eg, low PEF, low FEV1, low ratio, or emphysema on CT) PROB: PMH asthma HIGH PR: reversible PEF (with documented improvement) or onset<45 DEF: both criteria in HIGH PR Definite: plus highly probable/definite case Reviewer impression: COPD Emphysema Chronic bronchitis Asthma

Subtyping CLRD exacerbations CLRD exacerbation Is this a validated exacerbation? (ie, classified as a probable, highly probable, or definite CLRD exacerbation) If no, STOP Clear Subtype If the participant has validated asthma (probable, highly probable, or definite asthma) then classify as an asthma exacerbation If the participant has validated COPD (probable, highly probable, or definite COPD, emphysema, or chronic bronchitis) then classify as a COPD exacerbation Ambiguous Subtype If the participant has validated asthma AND validated COPD, emphysema, or chronic bronchitis, then classify as an asthma/copd exacerbation If the participant has no validated CLRD subtype, then classify as an unknown type of CLRD exacerbation Reviewer consensus If the participant has an ambiguous subtype by this algorithm, yet there is consensus among the reviewer impressions regarding the likely subtype, the Committee may choose to assign the consensus subtype (asthma OR COPD exacerbation)

QUESTION 1: Defining cases of chronic lower respiratory disease (CLRD). 1. Does this patient meet SOL criteria for CLRD? This question refers to whether this patient has a past medical history of CLRD OR a new diagnosis of CLRD. CLRD includes COPD, emphysema, chronic bronchitis, and asthma. Answer NO/UNKNOWN if the patient does not report a past medical history of CLRD, AND CLRD was not newly diagnosed during the admission, AND the patient was not chronically using CLRD medications prior to the admission. o If you answer NO/UNKNOWN to question 1, you should STOP. None of the subsequent questions are relevant. You may enter comments at Question 5. Definite, highly probable, and probable CLRD represent 3 levels of certainty for YES. SOL criteria for definite, highly probable, and probable are shown below. HCHS/SOL criteria for CHRONIC LOWER RESPIRATORY DISEASE (CLRD) Criteria for PROBABLE CLRD At least ONE of the following: Physician s diagnosis, either prior to (i.e., Past Medical History ) OR during the admission, defined as: COPD Chronic bronchitis Emphysema, OR Asthma Chronic use of medications for CLRD (prior to admission), defined as: Tiotropium (Spiriva) Atrovent or Combivent Inhaled corticosteroids Long-acting beta agonists (LABA)

Combination steroid/laba inhalers (e.g., Advair) Theophylline Roflumilast AND absence of a diagnosis of diffuse parenchymal lung disease Criteria for HIGHLY PROBABLE CLRD Probable CLRD, AND Intermediate objective evidence of airway obstruction or emphysema, as evidenced by at least one of the following: Physician s qualitative report of PFT results consistent with an obstructive ventilatory defect such as asthma or COPD, without quantitative report of FEV 1 /FVC values Physician s qualitative report of PEF results consistent with asthma or COPD, without quantitative report of PEF values Evidence of respiratory acidosis or CO2 retention, not likely to be secondary to obesity hypoventilation syndrome (OHS) as evidenced by BOTH of the following: On any arterial blood gas, pco2>50 with ph>7.4 No past medical history of obstructive sleep apnea or obesity hypoventilation syndrome Criteria for DEFINITE CLRD Probable CLRD, AND Definitive objective evidence of airway obstruction or emphysema, as evidenced by at least one of the following: Low PEF Low FEV 1 /FVC Flattened diaphragms, hyperinflation, or emphysema seen on chest X-ray Emphysema seen on CT scan NOTE: The peak expiratory flow (PEF) and pulmonary function tests (PFTs) referred to here are those in the medical record and not from the HCHS/SOL study visit. PFTs from the study visit will not be used to classify events. *See PFT criteria page for definitions of obstruction.

2a-2d. If YES (definite, highly probable, or probable), which sub-type(s) of CLRD does this patient have? NOTE: the sub-types of CLRD are NOT mutually exclusive. Please check off one box per subtype as noted below. 2a. Asthma. 2b. COPD. PROBABLE: Answer PROBABLE if there is a past medical history of asthma, or if a physician writes that the patient has asthma. HIGHLY PROBABLE: Answer HIGHLY PROBABLE if there is evidence for low PEF that reverses (with documented improvement in PEF or clinical status after treatment), OR if physicians write that the onset of asthma was prior to 45 years of age. DEFINITE: Answer DEFINITE if patient with a history of asthma has a low peak flow with improvement with bronchodilators AND the onset of asthma is documented as less than 45 years of age. PROBABLY NOT/NO: UNKNOWN: answer UNKNOWN if there is no evidence or conflicting evidence regarding whether the patient has asthma. PROBABLE: Answer PROBABLE if there is a past medical history of COPD, or if a physician writes that the patient has COPD. HIGHLY PROBABLE: Answer HIGHLY PROBABLE if there is qualitative evidence in the medical record for prior PFTs consistent with COPD (e.g., the patient has PFTconfirmed COPD ), without the quantitative PFT report. DEFINITE: Answer DEFINITE if quantitative PFT results are consistent with COPD. PROBABLY NOT/NO: Answer NO if PFTs (either quantitative or qualitative report) are not consistent with COPD. UNKNOWN: if there is no information regarding COPD, or if there is conflicting information as to whether the patient has COPD or not, then answer UNKNOWN. 2c. Emphysema. PROBABLE: Answer PROBABLE if there is a past medical history of emphysema, or if a physician writes that the patient has emphysema. DEFINITE: Answer DEFINITE if there is evidence of emphysema from a CT scan. You should also answer DEFINITE if the chest X-ray is consistent with emphysema (i.e., if it shows hyperinflation, emphysematous parenchymal changes, or flattened diaphragms).

PROBABLY NOT/NO: Answer NO if there is a normal CHEST CT in which the lung parenchyma is reported as normal. UNKNOWN: If there is no information or conflicting information as to whether the patient has emphysema or not, then answer UNKNOWN. 2d. Chronic Bronchitis. PROBABLE: Answer PROBABLE if there is a past medical history of chronic bronchitis, or if a physician writes that the patient has chronic bronchitis. HIGHLY PROBABLE: Answer HIGHLY PROBABLE if the patient meets criteria for PROBABLE, and the medical record also indicates a prior bronchitis-related event (hospitalization, ED visit, or urgent office visit) within the past 24 months. DEFINITE: Definite chronic bronchitis is only a clinical definition. Answer DEFINITE if cough for at least 3 months of the year for at least two years in a row is reported. PROBABLY NOT/NO: UNKNOWN: Answer UNKNOWN if there is no evidence or conflicting evidence regarding chronic bronchitis. QUESTION 3. In your opinion, which CLRD subtype do you think is predominant? Here, please use your clinical judgment to choose whether you think that the predominant underlying disease is COPD, emphysema, chronic bronchitis, OR asthma. These categories are mutually exclusive, so you may check ONLY one box. Please note that your answer to this question may be used to classify the sub-type of CLRD exacerbation (if present) as an asthma exacerbation or a COPD exacerbation (inclusive of COPD, emphysema, and chronic bronchitis). This may occur if there is no validated sub-type of CLRD, which would otherwise be used to assign the exacerbation sub-type. Please refer to the schematic for sub-typing CLRD exacerbations for clarification. QUESTION 4. Is there evidence of other lung disease? Answer NO, if there is not a history of other lung disease or if it is unknown if there is a history of other lung disease. Do not include pneumonia as other lung disease. If NO, then skip to question 3. Answer YES, if there is a history of a lung disease other than those reported above. 4a. IF yes, specify lung disease. Fill in the blank with the name of the other lung disease. Lung diseases of interest may include but are not limited to pulmonary sarcoidosis, Wegener s, interstitial lung disease, pulmonary fibrosis, pulmonary hypertension, pulmonary embolus, bronchiectasis, pneumoconiosis, and pneumonitis.

QUESTION 5. Does this patient have an exacerbation of chronic lower respiratory disease (CLRD)? Answer NO/UNKNOWN if the patient does not demonstrate signs OR symptoms of CLRD, or if these are not documented. You should then STOP. You may enter comments at Question 5. Definite, highly probable, and probable CLRD represent 3 levels of certainty for YES. SOL criteria for definite, highly probable, and probable are shown below. Criteria for PROBABLE CLRD exacerbation: Probable, highly probable, or definite CLRD, AND Signs OR symptoms of CLRD exacerbation: New onset or worsening symptoms of CLRD exacerbation, defined as: Dyspnea Cough Sputum production Wheeze Physical signs of CLRD exacerbation, defined as: Use of accessory muscles Respiratory distress Wheezing Prolonged expiratory time Criteria for HIGHLY PROBABLE CLRD exacerbation: Probable CLRD exacerbation, AND Receipt of systemic corticosteroids (PO/IV) during admission Criteria for DEFINITE CLRD exacerbation: Highly probable CLRD exacerbation

Highly probable or definite CLRD 5.a. If YES to #5 (definite, highly probable, or probable CLRD exacerbation), then was there evidence for an alternate explanation for the event? If there is objective evidence to suggest that the CLRD exacerbation may have been comorbid with another disease entity, such as acute decompensated heart failure or pneumonia and other conditions listed in question #4b, then indicate that this was a COMORBID CLRD exacerbation. If there was no objective evidence for any diagnosis besides CLRD, classify the event as a LONE CLRD exacerbation and SKIP to question 5 (COMMENTS). 5.b. If YES TO #5a (comorbid CLRD exacerbation), then indicate evidence for any of the following: 5.b.1. Pneumonia Answer YES if Pneumonia on chest X-ray and/or chest CT 5.b.2. Pulmonary Embolus Answer YES if Pulmonary embolus on CT and/or positive VQ scan 5.b.3. Pneumothorax Answer YES if Pneumothorax on X-ray and/or chest CT 5.b.4. Acute myocardial infarction. Answer YES if all of the following are present: Troponin/CK-MB greater than the upper limit of normal Acute ECG changes (ST segment elevation/depression, new Q waves) 5.b.5. Acute Decompensated Heart Failure. Answer YES if there is the presence of all of the following: Pulmonary vascular congestion on chest X-ray and/or CT BNP or ProBNP greater than the upper limit of normal with Creatinine less than upper limit of normal 5.b.6. Other. If you believe that there was a comorbid diagnosis not included on the above list, indicate OTHER and describe it in the next question 5b6a. IF YES to Other (c6), then what condition is comorbid? Fill in text box with comorbid condition. If YES to 5.b.5. for Acute Decompensated Heart Failure, please use your clinical judgment to indicate the predominant type of heart failure: 4b4a: Left-sided heart failure 4b4b: Right-sided heart failure 4b4d: Unclear if left, right, or biventricular heart failure 6. Comments. Write in any comments that you feel are pertinent to the classification of the event.

Criteria for Low Peak expiratory flow (PEF) and low FEV1/FVC ratio Low PEF is defined as PEF < 70% predicted. PEF predicted values will be based upon HCHS/SOL predicted values (currently pending) using age at time of clinical PEF measurement, gender, and measured height at HCHS/SOL exam. These 3 variables are included in the event summary form available with all medical records sent to reviewers. Low PEF w/ improvement is defined as an increase in PEF of 30% or, in absence of repeat PEF, clear improvement in clinical status. Low FEV1/FVC ratio is defined as pre-bronchodilator FEV1/FVC < LLN (lower limit of normal). The LLN for FEV1/FVC is based upon HCHS/SOL reference equations, determined on each individual patient, (currently pending) using age at time of clinical PFT measurement, gender, and measured height at HCHS/SOL exam. COPD from PFT results are based ideally on post-bronchodilator PFTS; however, if not available then pre-bronchodilator PFTs are used. The definition for COPD from post-bronchodilator PFTs is: 1) FEV1/FVC ratio <0.70 or <LLN. In absence of post-bronchodilator measures, the definition of COPD from pre-bronchodilator PFTS is: 1) FEV1/FVC ratio <0.70 or <LLN AND 2) FEV1 percent predicted <65%.